Development of a Robust Manufacturing Route for Molnupiravir, an Antiviral for the Treatment of COVID-19
Overview
Authors
Affiliations
Herein is described the development of a large-scale manufacturing process for molnupiravir, an orally dosed antiviral that was recently demonstrated to be efficacious for the treatment of patients with COVID-19. The yield, robustness, and efficiency of each of the five steps were improved, ultimately culminating in a 1.6-fold improvement in overall yield and a dramatic increase in the overall throughput compared to the baseline process.
Wommack A, Holloway A, Stallings K, Lundin P J Chem Educ. 2024; 101(3):1211-1217.
PMID: 38495616 PMC: 10938635. DOI: 10.1021/acs.jchemed.3c00999.
Streamlined Chemo-Enzymatic Synthesis of Molnupiravir via Lipase Catalyst.
Rosangzuala K, Patlolla R, Shaikh A, Naik K, Raveena G, Nemali M ACS Omega. 2024; 9(4):4423-4428.
PMID: 38313533 PMC: 10831972. DOI: 10.1021/acsomega.3c06872.
Sala S, Nitschke P, Masuda R, Gray N, Lawler N, Wood J J Proteome Res. 2024; 23(3):956-970.
PMID: 38310443 PMC: 10913068. DOI: 10.1021/acs.jproteome.3c00654.
Kawajiri T, Kijima A, Iimuro A, Ohashi E, Yamakawa K, Agura K ACS Cent Sci. 2023; 9(4):836-843.
PMID: 37122445 PMC: 10108738. DOI: 10.1021/acscentsci.2c01203.
Concise two-step chemical synthesis of molnupiravir.
Pereira V, Bezerra M, Gomez M, Martins G, da Silva A, de Oliveira K RSC Adv. 2022; 12(46):30120-30124.
PMID: 36329948 PMC: 9585438. DOI: 10.1039/d2ra05064a.